VRDN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRDN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-05), Viridian Therapeutics's share price is $11.60. Viridian Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.50. Therefore, Viridian Therapeutics's PE Ratio (TTM) for today is At Loss.
The historical rank and industry rank for Viridian Therapeutics's PE Ratio (TTM) or its related term are showing as below:
Viridian Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.79. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.50.
As of today (2024-06-05), Viridian Therapeutics's share price is $11.60. Viridian Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.50. Therefore, Viridian Therapeutics's PE Ratio without NRI for today is At Loss.
Viridian Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.79. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.50.
During the past 3 years, the average EPS without NRI Growth Rate was 22.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 27.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 40.10% per year.
During the past 12 years, Viridian Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 70.40% per year. The lowest was -1.90% per year. And the median was 26.10% per year.
Viridian Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.79. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.50.
The historical data trend for Viridian Therapeutics's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PE Ratio (TTM) | Get a 7-Day Free Trial | At Loss | At Loss | At Loss | At Loss | At Loss |
Viridian Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PE Ratio (TTM) | Get a 7-Day Free Trial | At Loss | At Loss | At Loss | At Loss | At Loss |
For the Biotechnology subindustry, Viridian Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Viridian Therapeutics's PE Ratio (TTM) for today is calculated as
PE Ratio (TTM) | = | Share Price | / | Earnings per Share (Diluted) (TTM) |
= | 11.60 | / | -4.500 | |
= | At Loss |
Viridian Therapeutics's Share Price of today is $11.60.
Viridian Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PE Ratio (TTM) | = | Market Cap | / | Net Income |
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Viridian Therapeutics (NAS:VRDN) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Thank you for viewing the detailed overview of Viridian Therapeutics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen F. Mahoney | director, officer: President and CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas W. Beetham | officer: Chief Operating Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Sarah Gheuens | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Seth Harmon | officer: See Remarks | C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453 |
Lara Meisner | officer: General Counsel and Secretary | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453 |
Scott Dunseth Myers | director, officer: Chief Executive Officer | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Jonathan Violin | officer: President and COO | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Barrett Katz | officer: Chief Medical Officer | 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301 |
Fairmount Healthcare Fund Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Carrie Melvin | officer: COO | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453 |
Frazier Life Sciences Public Fund, L.p. | 10 percent owner | TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101 |
L.p. Fhmlsp, | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Fhmlsp, L.l.c. | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Kristian Humer | officer: CFO and CBO | C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
Jennifer K. Moses | director | 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709 |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By Stock market mentor Stock market mentor • 02-06-2023
By Business Wire • 07-10-2023
By Business Wire Business Wire • 06-13-2023
By Business Wire Business Wire • 06-05-2023
By sperokesalga sperokesalga • 04-20-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 04-20-2023
By Business Wire • 01-18-2024
By Business Wire • 07-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.